+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Teratogen metabolism spontaneous decay products of thalidomide and thalidomide analogs are not bioactivated by liver microsomes



Teratogen metabolism spontaneous decay products of thalidomide and thalidomide analogs are not bioactivated by liver microsomes



Teratogenesis Carcinogenesis & Mutagenesis 5(3): 149-158



Thalidomide and 2 analogs, EM87 nad EM12, inhibited the attachment of tumor cells to concanavalin A-coated surfaces only if the drugs were first incubated with hepatic microsomes and cofactors. Most agents that inhibit attachment are demonstrated teratogens. Thalidomide undergoes spontaneous hydrolysis to at least 12 products in saline buffered to a pH of greater than 7. These hydrolysis products did not inhibit attachment nor could they be activated to inhibitory products with hepatic microsomes. Similarly EM12 and EM87 hydrolysis products were neither inhibitory nor substrates for activation. If the 3 drugs were incubated in buffered saline, there was a progressive decline in their ability to act as substrates for activation to an inhibitory product. It was possible to remove microsomes from the incubation mixture following drug activation by centrifugation. This microsome-free mixture inhibited cell attachment. When mouse ovarian tumor (MOT) cells were added to the microsome-free mixture, attachment was inhibited. However, if the activated drugs were incubated in saline, there was a progressive decline in their ability to inhibit attachment. Decay rates differed for the 3 compounds. At a pH of 7.4, thalidomide, EM87 and EM12 required 3 h, 1 h and 6 h, respectively, to decay to control levels. These relative rates of decay are consistent with the relative teratogenicity of the 3 drugs.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006587912

Download citation: RISBibTeXText

PMID: 2866599


Related references

Teratogen metabolism activation of thalidomide and thalidomide analogs to products that inhibit the attachment of cells to concanavalin a coated plastic surfaces. Biochemical Pharmacology 33(9): 1471-1478, 1984

Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts and in rat liver epithelial cells. Biochemical Pharmacology 62(8): 1081-1086, 15 October, 2001

The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. British Journal of Pharmacology and ChemoTherapy 25(2): 324-337, 1965

Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344). Biochemical Pharmacology 62(8): 1081-1086, 2001

The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. British Journal of Pharmacology and ChemoTherapy 25(2): 338-351, 1965

Metabolism of Thalidomide. I. the Spontaneous Hydrolysis of Thalidomide. Bollettino Della Societa Italiana di Biologia Sperimentale 39: 1921-1925, 1963

Thalidomide analogs part 7 the metabolism and elimination of the thalidomide like compound k 2004 2 bi cyclo 2.2.1 heptan 2 endo 3 endo dicarboximido glutarimide by the rat. Archiv der Pharmazie (Weinheim) 309(1): 62-69, 1976

Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. Journal of Pharmacology and Experimental Therapeutics 310(2): 571-577, 2004

Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicology and Applied Pharmacology 82(1): 175-179, 1986

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. Aids Research and Human Retroviruses 13(10): 857-863, 1997

Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts. Biochemical Pharmacology 53(10): 1553-1557, 1997

Thalidomide and thalidomide analogs suppress TNFalpha secretion by myocytes. Circulation 98(17 Suppl. ): I247, 1998

Thalidomide metabolites and analogs, part 3 Synthesis and antiangiogenic activity of the teratogenic and TNF-alpha-modulatory thalidomide analog EM-12. Abstracts of Papers American Chemical Society 222(1-2): MEDI264, 2001

Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity. Chemical Research in Toxicology 32(4): 589-602, 2019

Thalidomide embryopathy in animal experiments. 3. Teratologic tests of thalidomide catabolic products. Zeitschrift für Kinderheilkunde 96(2): 141-146, 1966